JNJ logo

Johnson & Johnson

JNJ
Healthcare|Drug Manufacturers - General|US
$276.22
+3.90 (+1.43%)
DCF Value
$295.64
Graham Number
$70.20
Cash / Share
$7.04

Analyst Consensus

Buy40 analysts
Strong Buy
0
Buy
21
Hold
16
Sell
3
Strong Sell
0
Consensus Target
$285.31
Implied Upside
+3.3%
Low Target
$260.00
High Target
$320.00

Price Target Trend

Last Month
$279.14
7 targets · +1% vs price
Last Quarter
$287.45
11 targets · +4% vs price
Last Year
$262.65
54 targets · -5% vs price
All Time
$220.58
111 targets · -20% vs price

Rating Trend

Dec 25
13 buy · 11 hold · 1 sell
Jan 26
14 buy · 11 hold · 1 sell
Feb 26
14 buy · 10 hold · 1 sell
Mar 26
14 buy · 10 hold · 1 sell
Apr 26
14 buy · 10 hold · 2 sell
May 26
15 buy · 10 hold · 1 sell
Jun 26
15 buy · 8 hold · 2 sell
Jul 26
16 buy · 7 hold · 1 sell
Aug 26
16 buy · 6 hold · 1 sell
Sep 26
16 buy · 6 hold · 1 sell
Oct 26
16 buy · 6 hold · 1 sell
Nov 26
16 buy · 6 hold · 1 sell

Recent Price Targets

DateFirmAnalystTargetPrice ThenSource
Oct 20, 2026Evercore ISI$300.00(+16%)$258.74StreetInsider
Oct 16, 2026Wells FargoLarry Biegelsen$287.00(+13%)$253.28TheFly
Oct 15, 2026BernsteinLee Hambright$270.00(+4%)$259.85StreetInsider
Oct 14, 2026RBC Capital$280.00(+11%)$251.68TheFly
Oct 14, 2026Leerink Partners$272.00(+8%)$251.75TheFly
Oct 14, 2026Wells FargoLarry Biegelsen$275.00(+11%)$248.61TheFly
Oct 14, 2026UBS$270.00(+9%)$248.61TheFly
Oct 6, 2026RBC CapitalShagun Singh$290.00(+15%)$252.93StreetInsider
Sep 29, 2026New Street$278.00(+2%)$271.95StreetInsider
Sep 10, 2026HSBC$320.00(+20%)$267.08TheFly
Sep 2, 2026UBS$320.00(+18%)$271.19TheFly
Aug 6, 2026Guggenheim$287.00(+11%)$257.59TheFly
Aug 3, 2026Raymond James$280.00(+10%)$254.45StreetInsider
Aug 3, 2026Wells Fargo$282.00(+10%)$256.35TheFly
Jul 29, 2026Argus ResearchDavid Toung$300.00(+13%)$266.13TheFly
Jul 16, 2026Johnson RiceIlya Zubkov$280.00(+12%)$249.75TheFly
Jul 16, 2026Scotiabank$305.00(+23%)$248.95TheFly
Jul 16, 2026Raymond James$265.00(+6%)$250.50TheFly
Jul 16, 2026Johnson Rice$261.00(+4%)$250.49StreetInsider
Jul 16, 2026Goldman Sachs$282.00(+14%)$247.02TheFly

Recent Rating Actions

FirmActionRatingDate
Wells FargomaintainOverweightOct 16, 2026
Morgan StanleymaintainOverweightOct 15, 2026
Leerink PartnersmaintainOutperformOct 14, 2026
RBC CapitalmaintainOutperformOct 14, 2026
Wells FargomaintainOverweightOct 14, 2026
GuggenheimmaintainBuyOct 7, 2026
RBC CapitalmaintainOutperformOct 6, 2026
CitigroupmaintainBuyOct 5, 2026
JP MorganmaintainNeutralSep 29, 2026
HSBCmaintainBuySep 10, 2026
UBSmaintainBuySep 2, 2026
GuggenheimmaintainBuyAug 6, 2026
Wells FargomaintainOverweightAug 3, 2026
GuggenheimmaintainBuyJul 17, 2026
Morgan StanleymaintainOverweightJul 16, 2026
RBC CapitalmaintainOutperformJul 16, 2026
Raymond JamesmaintainOutperformJul 16, 2026
Wells FargomaintainOverweightJul 16, 2026
RBC CapitalmaintainOutperformJul 13, 2026
TD CowenmaintainBuyJul 13, 2026
B of A SecuritiesmaintainNeutralJul 10, 2026
CitigroupmaintainBuyJul 8, 2026
Morgan StanleymaintainOverweightJul 8, 2026
GuggenheimmaintainBuyJun 26, 2026
Leerink PartnersupgradeMarket Perform →OutperformMay 13, 2026

Earnings History

Next report: Jan 26, 2027 · EPS est. $2.91
Report DateEPS ActualEPS Est.Revenue ActualRevenue Est.
Oct 13, 2026$2.59$2.52$25.40B$25.38B
Jul 15, 2026$2.90$2.85$25.31B$25.06B
Apr 14, 2026$2.70$2.68$24.06B$23.61B
Jan 21, 2026$2.46$2.46$24.56B$24.15B
Oct 14, 2025$2.80$2.76$23.99B$23.76B
Jul 16, 2025$2.77$2.68$23.74B$22.85B
Apr 15, 2025$2.77$2.58$21.89B$21.56B
Jan 22, 2025$2.04$1.99$22.52B$22.43B

News

Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer

Johnson and Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancerPR NewswireNEW BRUNSW

Nov 8, 2026gurufocus.com
Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer

First-of-its-kind dual-antigen-targeted bispecific regimen of pasritamig and JNJ-9401 directed at two prostate cancer proteins, KLK2 and PSMA, using complementary signals to activate T cells against cancer Deep and sustained PSA responses observed with every-six-week dosing, with 73% (11 of 15 patients) achieving reductions of at least 50% and nearly half achieving reductions of at least 90% in Phase 1 study With an encouraging safety profile, findings show potential for outpatient dosing as the…

Nov 8, 2026prnewswire.com
3 Dividend Stocks Worth Researching This Weekend

A quiet Sunday is a good time to look past the noise and study what actually lands in your account: cash dividends supported by real cash flow.

Nov 8, 2026247wallst.com
Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients

New patient experience data a to be presented at ACR 2026 show mouth dryness was reported as the most important symptom to improve, followed by eye dryness, fatigue and joint pain Patient insights complement Phase 2 study results demonstrating a 50% increase in saliva production b  in more than twice as many patients on nipocalimab compared to placebo c   Two Phase 3 studies are ongoing, evaluating nipocalimab in Sjögren's disease including these measures critical to patients NEW BRUNSWICK, N.J.…

Nov 7, 2026prnewswire.com
Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide

Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an ACR50 response at Week 16 ICOTYDE is a first-in-class IL-23R targeted oral peptide, demonstrating significant joint and skin improvements and a favorable safety profile in a once-daily pill NEW BRUNSWICK, N.J., Nov. 7, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive resul…

Nov 7, 2026prnewswire.com
J&J's once-daily pill eases psoriatic arthritis symptoms in late-stage trial

J&J's once-daily pill eases psoriatic arthritis symptoms in late-stage trial

Nov 7, 2026reuters.com
Johnson & Johnson $JNJ Shares Sold by Alps Advisors Inc.

Alps Advisors Inc. reduced its stake in shares of Johnson and Johnson (NYSE: JNJ) by 16.0% during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 177,499 shares of the company's stock after selling 33,788 shares during the quarter. Alps Advisors Inc.'s

Nov 7, 2026defenseworld.net
Johnson & Johnson $JNJ Shares Sold by Alps Advisors Inc.

Alps Advisors Inc. reduced its stake in shares of Johnson and Johnson (NYSE: JNJ) by 16.0% during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 177,499 shares of the company's stock after selling 33,788 shares during the quarter. Alps Advisors Inc.'s

Nov 7, 2026defenseworld.net
If Stocks Tumble This Winter, History Says Investors Who Make This 1 Move Come Out Ahead

Three words sum up this historically successful investing strategy.

Nov 7, 2026fool.com
The Average 1-Year CD Pays Just 1.76%. These Dividend Stocks Could Pay More

A guaranteed bank rate sounds safe until you weigh what it can't do.

Nov 6, 2026247wallst.com
4 Stocks I'm Not Selling Even If the Fed Keeps Raising Rates

Some companies will perform pretty well regardless of whether or not interest rates rise.

Nov 6, 2026fool.com
JNJ's Innovative Medicine Unit Grows in Q3 Despite Patent Losses

J&J's Innovative Medicine sees a 7.7% rise in Q3 sales to $16.76 billion, as blockbuster drugs and new launches offset generic headwinds.

Nov 6, 2026zacks.com
4 Dividend Raisers With Balance Sheets Strong Enough to Keep Raising Through Any Downturn

When profits dip, lenders get paid first and the dividend is usually what gets cut. Four household names have raised their payouts year after year, and one of them holds a credit rating almost no other U.S. company can match.

Nov 6, 2026247wallst.com
5 High-Yield Dividend Stocks That Could Hold Up When the Market Falls

Drugs, software, cereal, and electricity keep selling when the economy stalls. Five dividend payers pass a coverage test, but one carries a payout stretched thin and another faces a regulatory hearing that could change its income story.

Nov 6, 2026247wallst.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ

NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson ("J&J" or the "Company") (NYSE: JNJ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Nov 5, 2026prnewswire.com
Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer

Accelerated approval based on data demonstrating clinically meaningful efficacy, including a 42 percent overall response rate (95 percent confidence interval, 32–52 percent)1 First  advancement in the second-line treatment setting for recurrent or metastatic head and neck cancer in a decade, bringing a new subcutaneous option to patients with significant unmet need2-3   Extending its well-established, dual-targeted benefit beyond lung cancer,  RYBREVANT FASPRO™ targets both EGFR and MET pathways…

Nov 5, 2026prnewswire.com
4 Dividend Kings That Could Pay You for the Rest of Your Retirement

Retirees chasing big yields often get burned, so these four companies took a different route: raising payouts every year for over six decades. Which one has the most cushion, and which carries a risk that could rattle your portfolio?

Nov 5, 2026247wallst.com
BAYRY vs. JNJ: Which Stock Is the Better Value Option?

Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Bayer Aktiengesellschaft (BAYRY) and Johnson & Johnson (JNJ). But which of these two stocks is more attractive to value investors?

Nov 5, 2026zacks.com
2 Growth Stocks to Buy in November Without Any Hesitation

They have both outperformed the broader equity market over the long run.

Nov 5, 2026fool.com
3 Dependable Dividend Stocks for a $250,000 Passive Income Strategy

Some stocks are worth holding for decades, and they usually have one thing in common: a dividend that went up every year through recessions, rate shocks and bear markets.

Nov 5, 2026247wallst.com